Showing 51-60 of 1059 results for "".
Editor's Message
https://practicalneurology.com/columns/practice-management/PN0909_03-php/30889/Letters to the Editor
https://practicalneurology.com/columns/practice-management/PN0309_04-php/30935/Editor's Message
https://practicalneurology.com/columns/practice-management/0305_PN0305EditorMessage-pdf/31473/Editor's Message
https://practicalneurology.com/columns/practice-management/editors-message/30866/Editor's Message
https://practicalneurology.com/columns/practice-management/editors-message/30856/Letter to the Editor: At Face Value: Obama and Neurology
https://practicalneurology.com/columns/practice-management/1109_06-php/30875/Editor's Message: Should Expensive Therapies Be Avoided?
https://practicalneurology.com/columns/practice-management/editors-message-should-expensive-therapies-be-avoided/30792/From the Editor: New Additions to Practical Neurology® in 2018
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/from-the-editor-new-additions-to-practical-neurology-in-2018/30309/Where #Neurology and Culture Intersect- Letters to the Editor: The tPA Debate Continues: “Dr. Anonymous” Respondshttps://practicalneurology.com/columns/practice-management/letters-to-the-editor-the-tpa-debate-continues-dr-anonymous-responds/31488/Ongoing Debate on tPA Use in Acute Stroke ManagementAn anonymous physician from Oklahoma responds to prior discussions on the use of tissue plasminogen activator (tPA) in acute stroke treatment, emphasizing a cautious approach grounded in ethical and practical considerations. The physician clarifies
Letter to the Editor: A Clarification on Dalfampridine (Ampyra) Dosing and Other Data
https://practicalneurology.com/columns/practice-management/letter-to-the-editor-a-clarification-on-dalfampridine-ampyra-dosing-and-other-data/30855/